Tyme Technologies Stock News

Tyme Technologies press release (TYME): FQ3 GAAP EPS of -$0.03.The company is on track for mid-2022 full enrollment of HopES trial for SM-88 used in patients with high-risk Ewing’s…

TYME Technologies, Inc. (Nasdaq: TYME) (the Company or TYME), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™),

Tyme Technologies, Inc.'s (TYME) CEO Richie Cunningham on Q3 2022 Results - Earnings Call Transcript

BEDMINSTER, N.J.--(BUSINESS WIRE)--TYME Technologies, Inc. (Nasdaq: TYME) (the “Company” or “TYME”), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™),

Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Gilead Hit With FDA Partial Clinical Hold On Multiple Blood Cancer Studies Evaluating Magrolimab-Vidaz

TYME Technologies Inc (NASDAQ: TYME ) will discontinue SM-88 with MPS in the Precision Promise trial in metastatic pancreatic cancer (mPDAC). The trial''s sponsor, Pancreatic Cancer Action Network (PanCAN), terminated the arm due to futility compared to the control of the standard of Full story available on Benzinga.com

Biotech stocks posted losses for the third straight week, as the sector reacted to broader market weakness and announcements out of the 2022 JPMorgan Healthcare conference. Swiss biotech Molecular Par

The stock price of Tyme Technologies Inc (NASDAQ: TYME) fell by 1.66% in the most recent trading session. This is why it happened.

Tyme Technologies, Inc. (NASDAQ:TYME) with the stream of -3.63% also noticed, India Altice USA, Inc. (NYSE:ATUS) encountered a rapid change of 2.22% in the last hour of Thursdays trading session. The post Volume Movers: Tyme Technologies, Inc. (NASDAQ:TYME), Altice USA, Inc. (NYSE:ATUS) appeared first on Stocks Equity .

During the last session, Tyme Technologies Inc. (NASDAQ:TYME)s traded shares were 0.79 million, with the beta value of the company hitting 0.92. At the end of the trading day, the stocks price was $0.70, reflecting an intraday loss of -0.85% or -$0.01. The 52-week high for the TYME share is $4.99, that puts it down Tyme Technologies Inc. (NASDAQ: TYME)s Stock Is Down -38.25% Since The Beginning Of The Year, Likely To Sustain The Trend In 2021 Read More »

Tyme Technologies, Inc. (NASDAQ:TYME) with the stream of -1.30% also noticed, India Chewy, Inc. (NYSE:CHWY) encountered a rapid change of -0.71% in the last hour of Tuesdays trading session. Tyme The post Volume Sizzler: Tyme Technologies, Inc. (NASDAQ:TYME), Chewy, Inc. (NYSE:CHWY) appeared first on Stocks Equity .

BEDMINSTER, N.J.--(BUSINESS WIRE)--TYME Technologies, Inc. (Nasdaq: TYME) (the Company or TYME), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™), today announced encouraging preclinical data on the effect of TYME-19 in SARS CoV-2 infections. The Company believes that TYME-19, a synthetic bile acid, may have differentiated mechanisms that could offer alternatives for COVID-19 infected patients who may not be served by current and emerging oral agents. Bile

Tyme Technologies Inc. (NASDAQ:TYME)s traded shares stood at 0.61 million during the last session, with the companys beta value hitting 0.90. At the close of trading, the stocks price was $0.77, to imply a decrease of -0.08% or $0.0 in intraday trading. The TYME shares 52-week high remains $4.99, putting it -548.05% down since that Tyme Technologies Inc. (NASDAQ: TYME) Recovered 14.29% From The 52-Week Low, And Now Its -36.85% YTD This Is What You Do Now Read More »

Does Insider Buying Mean A Bullish Outlook For These Penny Stocks? The post 3 Hot Penny Stocks To Buy In December According To Insiders appeared first on Penny Stocks to Buy, Picks, News and Informati

TYME Technologies, Inc. (Nasdaq: TYME) (the Company or TYME), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs),